Foreign firms deny wrongdoing as Indian ministry points to trials 'deficiencies'
This article was originally published in Scrip
In its recent affidavit in an ongoing legal case concerning clinical trials, India's health ministry refers to certain past lapses of large companies including Pfizer, Sanofi and the contract services provider Quintiles in studies conducted at the Bhopal Memorial Hospital and Research Centre (BMHRC), although the firms involved strongly deny any wrongdoing.
You may also be interested in...
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.
The coronavirus pandemic has thrown up unprecedented challenges for the Indian clinical trials segment, as in other parts of the world. Experts tell Scrip how things are poised in the country including potential impact on some critical milestones, but efforts are underway to tackle the crisis.